Clinical
Trials
At BeiGene, we’re committed to bringing patients worldwide potential treatment options. We are currently recruiting clinical trials across areas including lymphoma, liver cancers, lung cancers, gastric cancers, breast cancers, and more.
-
A Study to Investigate BGB-3111 in Chinese Participants With B-cell Lymphoma
Condition:
B-cell Lymphoma
Molecule:BGB-3111
-
BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies
Condition:
B-cell Lymphoid Malignancies
Molecule:BGB-3111
-
Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
Condition:
Gastric Cancer
Molecule:Pamiparib
-
The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males
Condition:
Molecule:Zanubrutinib
-
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
Condition:
Esophageal Squamous Cell Carcinoma (ESCC)
Molecule:Tislelizumab
-
Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies
Condition:
Lymphoma, Leukemia
Molecule:BGB-3111 & BGB-A317
-
Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma (MAGNOLIA)
Condition:
Lymphoma
Molecule:Zanubrutinib
-
Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer
Condition:
Urothelial Bladder Cancer
Molecule:Tislelizumab
-
BGB-DXP604 Alone and in Combination With BGB DXP593 in Healthy Participants
Condition:
Molecule:BGB-DXP604 & BGB-DXP593
-
A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) (ASPEN)
Condition:
Waldenström's Macroglobulinemia
Molecule:BGB-3111
See All Trials
Clinical trials are an important part of our research and development efforts and help make possible access to safe and potentially life-saving treatments.
Off
This list includes trials with the following recruitment statuses: recruiting, enrolling by invitation, study start-up, not yet recruiting, and active/not recruiting.
